论文部分内容阅读
Objective. Catabolism and growth impairment are well-known complications of inflammatory bowel disease (IBD). This may be caused by the disease activity itself and/or the medical treatment, and both may lead to changes in the growth hormone (GH)/insulin-like growth factor I (IGF-I) axis. The aim of the present study was to examine the effects of enteral nutrition. Impact Powder(r), as adjuvant therapy to corticosteroid treatment on changes in the GH/IGF-I axis in patients with Crohn’ s disease (CD). Material and methods. The patients were randomized to 3-IP (ω -3-fatty acid (FA), 3 g/day) or 6-IP (ω -6-FA, 9 g/day). Changes in total IGF-I (tIGF-I) and total IGF-II (tIGF-II), free IGF-I (fIGF-I), IGF binding proteins (IGFBP-1 and IGFBP-3), IGFBP-3 protease activity and insulin levels were examined in 31 patients with active CD (CDAI: 186-603) during treatment with prednisolone (40 mg for 1 week) and tapering the dose by 5 mg/week. Clinical and biochemical markers of inflammation were studied at day 0, and after 5 and 9 weeks. Results. There were no differences at baseline between the two groups. During the treatment period, tIGFI, fIGF-I and IGFBP-3 increased significantly in both groups compared to baseline (p < 0.05) without differences between the groups. Insulin and IGFBP-1 showed no significant changes throughout the treatment period. Conclusions. There was no difference between 3-IP and 6-IP as adjuvant enteral nutrition on the GH/IGF-I axis. The changes observed in the GH/IGFI axis are in line with previously published studies and may be explained by corticosteroid treatment; however, we cannot exclude an additional effect of ω 3-/ω 6 FA as adjuvant enteral nutrition.
Objective. Catabolism and growth impairment are well-known complications of inflammatory bowel disease (IBD). This may be caused by the disease activity itself and / or the medical treatment, and both may lead to changes in the growth hormone (GH) / insulin The aim of the present study was to examine the effects of enteral nutrition. Impact Powder (r), as adjuvant therapy to corticosteroid treatment on changes in the GH / IGF-I axis in Patients with Crohn’s disease (CD). Material and methods. The patients were randomized to 3-IP (ω -3-fatty acid (FA), 3 g / day) or 6-IP g / day). Changes in total IGF-I (tIGF-I) and total IGF-II (tIGF-II), free IGF-I (fIGF-I), IGF binding proteins (IGFBP-1 and IGFBP- IGFBP-3 protease activity and insulin levels were examined in 31 patients with active CD (CDAI: 186-603) during treatment with prednisolone (40 mg for 1 week) and tapering the dose by 5 mg / week. Clinical and biochemical markers of inflammation were studied at day 0, and after 5 and 9 weeks. Results. There were no differences at baseline between the two groups. During the treatment period, tIGFI, fIGF-I and IGFBP-3 increased significantly in both groups compared to baseline (p < 0.05) without differences between the groups. Insulin and IGFBP-1 showed no significant changes throughout the treatment period. Conclusions. There was no difference between 3-IP and 6-IP as adjuvant enteral nutrition on the GH / IGF-I axis. changes observed in the GH / IGFI axis are in line with previously published studies and may be explained by corticosteroid treatment; however, we can not exclude an additional effect of ω 3- / ω 6 FA as adjuvant enteral nutrition.